Parameters Important for Clinical Use:
Around 30,000 users tested in 5 clinical trials e.g. in 2 clinical trials where 415 subjects were tested with both Corowell test and PCR at the same time – only one false negative and one false positive.
Sensitivity versus PCR validated in multiple clinical trials with 415 people of 96.4% Corowell is effective at early detection of COVID 19 symptoms as a screening tool and people suspected of infection the earliest than any other test on the market today.
Hyposmia (partial loss of the sense of smell) is the most suitable indicator for early COVID-19 detection occurring in up to 87% of those infected in the first 9 days after infection long before any other symptoms develop. Anosmia is the loss of smell and that occurs in about 13% of those infected and occurs in a much later stage of infection when other moderate symptoms are also present.
RAPID ANTIGEN TESTS AS AN EARLY DETECTOR OF INFECTION:
Hyposmia (partial loss of the sense of smell) is the most suitable indicator for early COVID-19.
Watch Our Video